Oncomine (www.oncomine.org) analysis also showed that the majority of the prostate cancer patients evaluated had elevated expression levels of ARF1 being about 3.5- and 2.5-fold higher in prostate adenocarcinoma and carcinoma, respectively, than in normal prostate gland (Data not shown). This evidence concerns the gene ARF1 and prostate adenocarcinoma.